Merck & Co., Inc. (NYSE:MRK) Holdings Raised by Benchmark Financial Wealth Advisors LLC

Benchmark Financial Wealth Advisors LLC boosted its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 11.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,988 shares of the company’s stock after acquiring an additional 406 shares during the quarter. Benchmark Financial Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $435,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Ruedi Wealth Management Inc. raised its holdings in shares of Merck & Co., Inc. by 180.2% during the 3rd quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock valued at $32,000 after purchasing an additional 200 shares in the last quarter. AlphaMark Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $34,000. Valued Wealth Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $42,000. TFO Wealth Partners LLC raised its holdings in shares of Merck & Co., Inc. by 108.1% during the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock valued at $48,000 after purchasing an additional 241 shares in the last quarter. Finally, Ameliora Wealth Management Ltd. bought a new position in shares of Merck & Co., Inc. during the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Activity

In other news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at approximately $2,991,346.35. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the transaction, the executive vice president now directly owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

MRK has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, March 27th. Truist Financial reiterated a “buy” rating and issued a $142.00 target price (up previously from $139.00) on shares of Merck & Co., Inc. in a report on Thursday, March 28th. UBS Group lifted their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a report on Monday, March 4th. Finally, Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price on the stock. in a report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $129.71.

Read Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

NYSE MRK traded down $0.64 during midday trading on Tuesday, hitting $130.35. The company had a trading volume of 6,550,741 shares, compared to its average volume of 8,717,681. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. The stock has a market cap of $330.13 billion, a price-to-earnings ratio of 935.21, a P/E/G ratio of 0.52 and a beta of 0.38. The firm has a fifty day simple moving average of $125.24 and a two-hundred day simple moving average of $113.04. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.12. The company had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the business posted $1.62 EPS. Equities analysts forecast that Merck & Co., Inc. will post 8.59 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 2.36%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 2,200.00%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.